NORML Testifies to End Employment Discrimination of MMJ Patients in DC

Generic 28 September 2019 | 0 Comments

On Wednesday, September 25th, 2019, NORML testified at the DC Council Committee on Labor and Workforce Development in support of B23-0309, the “Medical Marijuana Program Patient Employment Protection Amendment Act of 2019”, which seeks to expand workplace protections for medical cannabis patients in the District of Columbia. 

Dozens of District residents, medical cannabis patients, and advocates came to speak in favor of ending the practice of randomly testing public employees and/or those seeking employment for their off-the-job use of cannabis. DC Advisory Neighborhood Commissioners (ANCs) and unions also came out to speak on behalf of their constituencies and union members in support of the proposed legislation. The hearing lasted more than seven hours. 

Councilmembers Elissa Silverman (Committee Chair and At-Large Councilmember), David Grosso (At-Large Councilmember), and Trayon White (Ward 8 Councilmember) interacted with witnesses in rounds of questioning to clarify points made in witness testimony. By the time NORML left the witness panel — after an hour of testimony and questioning — the science was made clear: Medical cannabis patients do not present any greater risk to workplace safety, and drug testing for cannabis metabolites does not provide any means of determining whether someone is impaired on the job. You can read more about NORML’s position on cannabis in the workplace here

You can view the hearing by clicking here. NORML’s testimony begins at 32:00. You can also read NORML’s submitted written testimony here

Tagged in ,

Leave a Reply